|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
03737 ZHONGZHIPHARM
Nominal 
0.670 -0.020 (-2.899%) | 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Turnover | 880,480 | -19.105% | 2,214,783 | 2,049,812 | 1,825,935 | 1,746,500 |
| Cost of Sales | (397,962) | -13.745% | (926,376) | (831,669) | (753,640) | (685,061) |
| Gross Profit | 482,518 | -23.049% | 1,288,407 | 1,218,143 | 1,072,295 | 1,061,439 |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (2,772) | -- | (4,100) | (474) | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | 600 | -99.429% | 146,897 | 207,581 | 130,651 | 61,813 | |
| Taxation | 8,217 | -- | (50,750) | (43,447) | (23,736) | (9,447) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (34) | -95.813% | (935) | (1,359) | (528) | (238) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 8,783 | -89.474% | 95,212 | 162,775 | 106,387 | 52,128 | |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 760 | -56.196% | 1,855 | 883 | 2,667 | 2,938 |
| Depreciation & Amortisation | 47,406 | -7.144% | 111,421 | 102,079 | 96,384 | 85,052 |
| Directors' Emoluments | -- | -- | 10,668 | 6,586 | 6,090 | 5,377 |
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified (Modified Report) | Unqualified |
Market Valuation Indicators
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| EPS (cts) | 1.000 | -89.899% | 11.000 | 19.000 | 13.000 | 6.000 |
| DPS (cts) | 0.000 | -- | 4.615 | 8.170 | 7.880 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | 41.952% | 43.000% | 60.612% | -- |
| Cash flow per share ($) | -- | -- | 0.215 | 0.120 | 0.336 | 0.213 |
| NBV per share ($) | 1.257 | -- | 1.293 | 1.214 | 1.161 | 1.041 |
| Remarks: | Real time quote last updated: 11/09/2025 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 8,783 |
| %Change | -89.474% |
| EPS / (LPS) | RMB 0.010 |
| NBV Per Share (¥) | RMB 1.257 |